SEC Form 4 · accession 0001209191-15-075198

Aclaris Therapeutics, Inc. · ACRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

Vivo Ventures Fund VII, L.P.

10% Owner

Vivo Ventures VII Affiliates Fund, L.P.

10% Owner

VIVO VENTURES VII, LLC

10% Owner

Period of report

Oct 13, 2015

Accepted (ET)

Oct 13, 2015 · 1:29 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001557746

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Oct 13, 2015	C	3,360,408	—	A	3,657,147	I	By Vivo Ventures Fund VII, L.P.
Common Stock^F3	Oct 13, 2015	P	444,850	$11.00	A	4,101,997	I	By Vivo Ventures Fund VII, L.P.
Common Stock^F1,F2,F4	Oct 13, 2015	C	73,238	—	A	79,705	I	By Vivo Ventures VII Affiliates Fund, L.P.
Common Stock^F4	Oct 13, 2015	P	9,695	$11.00	A	89,400	I	By Vivo Ventures VII Affiliates Fund, L.P.

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F3,F2	—	Oct 13, 2015	C	8,467,943	D	—	—	Common Stock	2,454,476	I
Series A Preferred Stock^F4,F2	—	Oct 13, 2015	C	184,557	D	—	—	Common Stock	53,494	I
Series B Preferred Stock^F3,F2	—	Oct 13, 2015	C	1,779,400	D	—	—	Common Stock	515,768	I
Series B Preferred Stock^F4,F2	—	Oct 13, 2015	C	38,782	D	—	—	Common Stock	11,241	I
Series C Preferred Stock^F3,F2	—	Oct 13, 2015	C	1,346,068	D	—	—	Common Stock	390,164	I
Series C Preferred Stock^F4,F2	—	Oct 13, 2015	C	29,337	D	—	—	Common Stock	8,503	I

Explanation of responses

F1The total represents shares received upon conversion of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock.
F2Effective upon the closing of the issuer's initial public offering of its common stock, each share of preferred stock automatically converted into 0.289855 shares of common stock. The preferred stock had no expiration date.
F3Vivo Ventures VII, LLC ("VV LLC") is the general partner of Vivo Ventures Fund VII, L.P. ("VVF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F4VV LLC is the general partner of Vivo Ventures VII Affiliates Fund, L.P. ("VVAF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVAF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.